Literature DB >> 18241227

Human leucocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity.

R J Boyton1, J Smith, M Jones, C Reynolds, L Ozerovitch, A Chaudhry, R Wilson, M Rose, D M Altmann.   

Abstract

The aetiology of idiopathic bronchiectasis, a lung disease where chronic inflammation and bacterial infection leads to progressive lung damage, is unknown. A possible role for natural killer cells has been highlighted previously. However, a role for adaptive immunity is suggested by the presence of CD4 and CD8 T cells in diseased lung tissue. Evidence of a human leucocyte antigen (HLA) class II disease association would further implicate a role for adaptive immunity. To establish if there is any HLA association, we analysed HLA-A, HLA-B, HLA-DQA1, HLA-DQB1 and HLA-DRB1 alleles in patients with idiopathic bronchiectasis and controls. Genomic DNA from 92 adults with idiopathic bronchiectasis and 101 healthy controls was analysed by polymerase chain reaction with sequence-specific primers. We found an increase in the prevalence of HLA-DRB1*01 DQA1*01/DQB1*05 genes in idiopathic bronchiectasis; that is, the HLA-DR1, DQ5 haplotype (odds ratio 2.19, 95% confidence interval 1.15-4.16, P = 0.0152) compared with control subjects. The association with HLA-DR1, DQ5 implicates a role for CD4 T cells restricted by these molecules in susceptibility to the progressive lung damage seen in this disease. This may operate either through influencing susceptibility to specific pathogens or to self-reactivity and requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18241227      PMCID: PMC2384066          DOI: 10.1111/j.1365-2249.2008.03596.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

Review 1.  Bronchiectasis in systemic diseases.

Authors:  M Cohen; S A Sahn
Journal:  Chest       Date:  1999-10       Impact factor: 9.410

2.  An investigation into causative factors in patients with bronchiectasis.

Authors:  M C Pasteur; S M Helliwell; S J Houghton; S C Webb; J E Foweraker; R A Coulden; C D Flower; D Bilton; M T Keogan
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

Review 3.  TAP deficiency syndrome.

Authors:  S D Gadola; H T Moins-Teisserenc; J Trowsdale; W L Gross; V Cerundolo
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 4.  Genetics of infectious diseases.

Authors:  Angela J Frodsham; Adrian V S Hill
Journal:  Hum Mol Genet       Date:  2004-10-01       Impact factor: 6.150

5.  Bronchial inflammation and colonization in patients with clinically stable bronchiectasis.

Authors:  J Angrill; C Agustí; R De Celis; X Filella; A Rañó; M Elena; J P De La Bellacasa; A Xaubet; A Torres
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

6.  Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A.

Authors:  S M Smith; R Brookes; M R Klein; A S Malin; P T Lukey; A S King; G S Ogg; A V Hill; H M Dockrell
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

7.  IL-12-activated NK cells reduce lung eosinophilia to the attachment protein of respiratory syncytial virus but do not enhance the severity of illness in CD8 T cell-immunodeficient conditions.

Authors:  T Hussell; P J Openshaw
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

8.  Analysis of HLA antigens in Mycobacterium avium-intracellulare pulmonary infection.

Authors:  K Kubo; Y Yamazaki; M Hanaoka; H Nomura; K Fujimoto; T Honda; M Ota; Y Kamijou
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

9.  NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen.

Authors:  Ramakrishna Vankayalapati; Peter Klucar; Benjamin Wizel; Stephen E Weis; Buka Samten; Hassan Safi; Homayoun Shams; Peter F Barnes
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

10.  Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.

Authors:  Maureen P Martin; Ying Qi; Xiaojiang Gao; Eriko Yamada; Jeffrey N Martin; Florencia Pereyra; Sara Colombo; Elizabeth E Brown; W Lesley Shupert; John Phair; James J Goedert; Susan Buchbinder; Gregory D Kirk; Amalio Telenti; Mark Connors; Stephen J O'Brien; Bruce D Walker; Peter Parham; Steven G Deeks; Daniel W McVicar; Mary Carrington
Journal:  Nat Genet       Date:  2007-05-13       Impact factor: 38.330

View more
  10 in total

1.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

Authors:  Amy E Seitz; Kenneth N Olivier; Jennifer Adjemian; Steven M Holland; D Rebecca Prevots
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

2.  Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study.

Authors:  Carlotta Nannini; Yimy F Medina-Velasquez; Sara J Achenbach; Cynthia S Crowson; Jay H Ryu; Robert Vassallo; Sherine E Gabriel; Eric L Matteson; Tim Bongartz
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-08       Impact factor: 4.794

3.  Chronic Infection by Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F.

Authors:  Kathryn J Quigley; Catherine J Reynolds; Amelie Goudet; Eleanor J Raynsford; Ruhena Sergeant; Andrew Quigley; Stefan Worgall; Diana Bilton; Robert Wilson; Michael R Loebinger; Bernard Maillere; Daniel M Altmann; Rosemary J Boyton
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

4.  Correlation between systemic inflammatory response and quality of life in patients with chronic rhinosinusitis.

Authors:  Quinn Orb; Abigail Pulsipher; Kristine A Smith; Shaelene Ashby; Jeremiah A Alt
Journal:  Int Forum Allergy Rhinol       Date:  2019-01-18       Impact factor: 3.858

5.  Increased susceptibility to organic dust exposure-induced inflammatory lung disease with enhanced rheumatoid arthritis-associated autoantigen expression in HLA-DR4 transgenic mice.

Authors:  Jill A Poole; Ted R Mikuls; Geoffrey M Thiele; Rohit Gaurav; Amy J Nelson; Michael J Duryee; Ananya Mitra; Carlos Hunter; Todd A Wyatt; Bryant R England; Dana P Ascherman
Journal:  Respir Res       Date:  2022-06-18

6.  Total IgA and IgA reactivity to antigen I/II epitopes in HLA-DRB1*04 positive subjects.

Authors:  V Wallace McCarlie; James K Hartsfield; Janice S Blum; Carlos González-Cabezas; Judith R Chin; George J Eckert; Lorri A Morford; Mark D Pescovitz; Henry Rodriguez; Margherita Fontana; Richard L Gregory
Journal:  Open J Immunol       Date:  2013-09-01

7.  Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease.

Authors:  Fathia G Jaat; Sajidah F Hasan; Audrey Perry; Sharon Cookson; Santosh Murali; John D Perry; Clare V Lanyon; Anthony De Soyza; Stephen M Todryk
Journal:  Respir Res       Date:  2018-05-30

8.  Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors.

Authors:  Natsuko Suginobe; Megumi Nakamura; Yosuke Takanashi; Hitoshi Ban; Masashi Gotoh
Journal:  Clin Transl Oncol       Date:  2022-09-23       Impact factor: 3.340

Review 9.  Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis.

Authors:  R J Boyton; C J Reynolds; K J Quigley; D M Altmann
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

10.  The immune response and its therapeutic modulation in bronchiectasis.

Authors:  Massoud Daheshia; James D Prahl; Jacob J Carmichael; John S Parrish; Gilbert Seda
Journal:  Pulm Med       Date:  2012-10-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.